PerkinElmer (NYSE:PKI) insider Daniel R. Tereau sold 1,156 shares of the firm’s stock in a transaction on Wednesday, April 18th. The stock was sold at an average price of $77.00, for a total transaction of $89,012.00. Following the completion of the sale, the insider now owns 6,784 shares in the company, valued at $522,368. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
PKI stock traded up $0.12 during trading on Friday, hitting $75.22. 99,877 shares of the stock traded hands, compared to its average volume of 663,428. PerkinElmer has a one year low of $56.98 and a one year high of $84.49. The company has a market capitalization of $8,442.53, a P/E ratio of 26.16, a P/E/G ratio of 2.11 and a beta of 0.81. The company has a quick ratio of 0.89, a current ratio of 1.26 and a debt-to-equity ratio of 0.71.
PerkinElmer (NYSE:PKI) last announced its quarterly earnings results on Thursday, January 25th. The medical research company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.03. PerkinElmer had a net margin of 12.97% and a return on equity of 13.30%. The firm had revenue of $641.63 million during the quarter, compared to the consensus estimate of $619.14 million. During the same period last year, the firm posted $0.83 EPS. The firm’s quarterly revenue was up 13.2% on a year-over-year basis. research analysts expect that PerkinElmer will post 3.52 earnings per share for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in shares of PerkinElmer by 53.8% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,228 shares of the medical research company’s stock worth $170,000 after acquiring an additional 779 shares during the last quarter. Cutler Group LP raised its stake in shares of PerkinElmer by 845.7% in the fourth quarter. Cutler Group LP now owns 2,237 shares of the medical research company’s stock worth $163,000 after acquiring an additional 2,537 shares during the last quarter. Signition LP bought a new position in shares of PerkinElmer in the fourth quarter worth about $207,000. SSI Investment Management Inc. bought a new position in shares of PerkinElmer in the fourth quarter worth about $209,000. Finally, Howe & Rusling Inc. bought a new position in shares of PerkinElmer in the fourth quarter worth about $234,000. 91.93% of the stock is owned by institutional investors.
PKI has been the subject of a number of analyst reports. Morgan Stanley reduced their price objective on shares of PerkinElmer from $89.00 to $85.00 and set an “overweight” rating for the company in a report on Wednesday, April 11th. Deutsche Bank reduced their price objective on shares of PerkinElmer from $85.00 to $80.00 and set a “hold” rating for the company in a report on Monday, April 9th. Robert W. Baird reaffirmed a “buy” rating and set a $88.00 price objective on shares of PerkinElmer in a report on Friday, January 26th. Barclays raised their price objective on shares of PerkinElmer from $69.00 to $73.00 and gave the stock an “underweight” rating in a report on Friday, January 26th. Finally, Cowen reaffirmed a “hold” rating and set a $84.00 price objective on shares of PerkinElmer in a report on Friday, January 26th. One analyst has rated the stock with a sell rating, ten have given a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $77.57.
WARNING: This news story was published by Week Herald and is the sole property of of Week Herald. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://weekherald.com/2018/04/20/perkinelmer-pki-insider-daniel-r-tereau-sells-1156-shares.html.
PerkinElmer Company Profile
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment develops and offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil.
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.